Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PPIA | P62937 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9175696 | 0.91 | P2RX7 (0.33) | P2RX7KMT2ACTSLMEN1MAPK1 | |
| SCHEMBL89757 | 0.89 | PPIA (0.37) | P2RX7KMT2ACTSLMEN1MAPK1 | |
| SCHEMBL2809077 | 0.86 | P2RX7 (0.41) | P2RX7KMT2ACTSLMEN1MAPK1 | |
| SCHEMBL17606749 | 0.84 | TDP1 (0.36) | P2RX7KMT2ACTSLMEN1MAPK1 | |
| SCHEMBL6703818 | 0.84 | P2RX7 (0.35) | P2RX7KMT2ACTSLMEN1MAPK1 | |
| SCHEMBL28074491 | 0.84 | CTSK (0.33) | P2RX7KMT2ACTSLMEN1MAPK1 | |
| SCHEMBL22015821 | 0.83 | APLNR (0.36) | P2RX7KMT2ACTSLMEN1MAPK1 | |
| SCHEMBL23538780 | 0.82 | P2RX7 (0.34) | P2RX7KMT2ACTSLMEN1MAPK1 | |
| SCHEMBL29420344 | 0.82 | USP2 (0.38) | P2RX7KMT2ACTSLMEN1MAPK1 | |
| SCHEMBL23538650 | 0.82 | P2RX7 (0.34) | P2RX7KMT2ACTSLMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114787167-B | Compounds and compositions for the treatment of parasitic diseases | 诺华股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| CN-114787167-A | Compounds and compositions for the treatment of parasitic diseases | 诺华股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021078120-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-29 | — | — | WO | disclosed |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-22 | — | — | US | disclosed |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-2511276-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | Ube Industries, Ltd. (JP) | 2012-10-17 | — | — | EP | disclosed |
| EP-2511276-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | Ube Industries, Ltd. (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| CN-102482281-A | Pyrrolo [2,3-D ] pyrimidine derivatives | DAIICHI SANKYO CO LTD | 2012-05-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | ABCB11, SQLE, FURIN | P2RX7 2570/4885KMT2A 1436/4885CTSL 1066/4885 |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | P2RX7 2144/4885KMT2A 3467/4885CTSL 484/4885 |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | ABCB11, SQLE, FURIN | P2RX7 2570/4885KMT2A 1436/4885CTSL 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.